Home Cart Sign in  
Chemical Structure| 1314883-11-8 Chemical Structure| 1314883-11-8

Structure of MMV390048
CAS No.: 1314883-11-8

Chemical Structure| 1314883-11-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MMV390048 is an antimalarial compound belonging to the aminopyridine class for treating malaria. It is efficacious against all Plasmodium life cycle stages, apart from late hypnozoites in the liver.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MMV390048

CAS No. :1314883-11-8
Formula : C18H14F3N3O2S
M.W : 393.38
SMILES Code : NC1=NC=C(C2=CC=C(S(=O)(C)=O)C=C2)C=C1C3=CC=C(C(F)(F)F)N=C3
MDL No. :MFCD28502126
InChI Key :RTJQABCNNLMCJF-UHFFFAOYSA-N
Pubchem ID :53311393

Safety of MMV390048

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of MMV390048

PI3K-AKT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Plasmodium falciparum gametocytes (stages I-III and IV-V, luciferase-expressing) 214 nM (I-III), 140 nM (IV-V) Assess the activity of MMV390048 against different stages of gametocytes, showing faster killing of late-stage gametocytes Sci Transl Med. 2017 Apr 26;9(387):eaad9735
Babesia gibsoni (Oita strain) 100, 50, 25, 10, 5, 1 μM 96 hours To evaluate the in vitro anti-Babesia activity of MMV390048, with an IC50 value of 6.9 ± 0.9 μM. Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0057422
Plasmodium falciparum gametocytes (stages IV and V) 285 nM Evaluate the effect of MMV390048 on gametocyte viability, showing inhibition of late-stage gametocytes Sci Transl Med. 2017 Apr 26;9(387):eaad9735
Plasmodium falciparum NF54 strain 28 nM (IC50), 40 nM (IC90) 48 hours Evaluate the inhibitory activity of MMV390048 against the intraerythrocytic life cycle stages of P. falciparum, showing high efficacy against the NF54 strain Sci Transl Med. 2017 Apr 26;9(387):eaad9735

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Plasmodium berghei infection model Oral 1.1 mg/kg (ED90), 0.57 mg/kg (ED50) Four doses (4, 24, 48, and 72 hours post-infection) Evaluate the efficacy of MMV390048 in a mouse malaria model, showing high efficacy and complete cure Sci Transl Med. 2017 Apr 26;9(387):eaad9735
Rat Embryofetal developmental studies Oral 2, 6, 20, 40, 60 mg/kg/day Once daily from GD6 to GD17 Evaluate the embryofetal toxicity of MMV390048 in rats, observed diaphragmatic hernias and cardiovascular malformations Birth Defects Res. 2022 Jun;114(10):487-498
SCID mice Babesia microti infection model Oral 20 mg/kg 64 consecutive days To evaluate the radical cure effect of MMV390048 on Babesia microti infection, results showed that parasites were cleared after 64 days of continuous treatment. Front Cell Infect Microbiol. 2022 Nov 14;12:1048962
BALB/c mice and SCID mice B. microti (Peabody mjr strain) and B. rodhaini (Australia strain) infection models Oral 20 mg/kg 7 consecutive days, starting at 4 DPI To evaluate the in vivo anti-Babesia activity of MMV390048 against B. microti and B. rodhaini. Results showed that MMV390048 significantly inhibited parasite growth and prevented anemia development. Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0057422

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03195387 Malaria,Falciparum PHASE1 WITHDRAWN 2025-12-18 Institute of Tropical Medicine... More >> / Centre for Clinical Trials, Eberhard Karls University, Tübingen, 72074, Germany Less <<
NCT02880241 Malaria PHASE2 TERMINATED 2018-09-24 University of Gondar Hospital/... More >>Maksegnit Health Centre, Gondar, Amhara, 6200, Ethiopia|Jimma University Referral Hospital/Agaro District Hospital, Jimma, Oromia, Ethiopia Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.54mL

0.51mL

0.25mL

12.71mL

2.54mL

1.27mL

25.42mL

5.08mL

2.54mL

References

 

Historical Records

Categories